Sign in

CIK 0001512762

  • Accelerated filer
  • Smaller reporting company

Coherus Oncology, Inc.

Sign in to watch
Ticker
CHRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
273615821
Phone
+1 650-649-3530
Business address
C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
Former names
Coherus BioSciences, Inc., BioGenerics, Inc.
  1. 4/A Derivatives Options or other derivatives
  2. 4/A Derivatives Options or other derivatives
  3. 4/A Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 3 Insider Initial Statement of Ownership
  6. 4 Shares withheld for taxes Chief Scientific Officer gave up 7,733 shares (to pay taxes)
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Grant or award President & CEO acquired 86,250 shares (grant or award)
  12. 4 Grant or award Chief Financial Officer acquired 40,000 shares (grant or award)
  13. 4 Grant or award Chief Scientific Officer acquired 40,000 shares (grant or award)
  14. 4 Gift President & CEO gave 10,000 shares (gift)
  15. 4 Open-market sale Chief Financial Officer sold 3,507 shares at $16.80 ($58,919)
  16. 4 Open-market sale Director sold 434,555 shares at an average $16.68 ($7,250,063)
  17. 4 Grant or award Chief Operating Officer acquired 50,000 shares (grant or award)
  18. 4 Open-market buy Chief Financial Officer bought 3,700 shares at $13.42 ($49,668)
  19. 4 Open-market sale President & CEO sold 31,054 shares at $13.56 ($421,229)
  20. 4 Derivatives Options or other derivatives

Page 6 of 20 · 399 filings